| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $180.1M | — |
| Cost of Revenue | $6.2M | — |
| R&D Expense | $236.7M | -13.1% |
| SG&A Expense | $435.1M | +302.3% |
| Operating Income | -$497.9M | -30.8% |
| Income Tax | $0 | — |
| Net Income | -$465.9M | -24.7% |
| EPS (Basic) | -$21.90 | -9.6% |
| EPS (Diluted) | -$21.90 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $100.0M | +0.1% |
| Accounts Receivable | $53.8M | — |
| Inventory | $34.1M | — |
| Current Assets | $1.03B | +62.1% |
| Total Assets | $1.04B | +62.7% |
| Current Liabilities | $169.3M | +42.8% |
| Long-term Debt | $117.6M | +1.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$455.6M | -40.5% |
| Capital Expenditures | $1.5M | -1.1% |
| Investing Cash Flow | -$274.4M | +45.4% |
| Financing Cash Flow | $735.1M | +23.5% |
| Free Cash Flow | -$457.0M | -40.3% |
| Total Liabilities |
| $287.9M |
| +22.4% |
| Stockholders' Equity | $754.4M | +86.1% |